BRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula Submissions

Reuters

Dec 29, 2025

BRIEF-<a href="https://laohu8.com/S/BUBSF">Bubs Australia</a> Says FDA Continues Review Of Bubs' Infant Formula Submissions

Dec 29 (Reuters) - Bubs Australia Ltd BUB.AX:

FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONS
CONFIRMS THAT IT IS ON TRACK TO RECEIVE FDA APPROVAL
FDA CONFIRMED IT WILL CONTINUE TO FACILITATE IMPORTATION, OTHERS OF BUBS' INFANT FORMULA PRODUCTS IN US AFTER 31 DEC 2025

Further company coverage: BUB.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595277199"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595277199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595277199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595277199","market":"us","top_or_hot":-1,"title":"BRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula Submissions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/BUBSF\">Bubs Australia</a> Says FDA Continues Review Of Bubs' Infant Formula Submissions</title></head><body><p><span>Dec 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BUB.AU\">Bubs Australia</a> Ltd <span>BUB.AX</span>:</p><ul><li><p>FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONS</p></li><li><p>CONFIRMS THAT IT IS ON TRACK TO RECEIVE FDA APPROVAL</p></li><li><p>FDA CONFIRMED IT WILL CONTINUE TO FACILITATE IMPORTATION, OTHERS OF BUBS' INFANT FORMULA PRODUCTS IN US AFTER 31 DEC 2025</p></li></ul><p>Further company coverage: <span>BUB.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula Submissions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula Submissions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-29 09:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/BUBSF\">Bubs Australia</a> Says FDA Continues Review Of Bubs' Infant Formula Submissions</title></head><body><p><span>Dec 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BUB.AU\">Bubs Australia</a> Ltd <span>BUB.AX</span>:</p><ul><li><p>FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONS</p></li><li><p>CONFIRMS THAT IT IS ON TRACK TO RECEIVE FDA APPROVAL</p></li><li><p>FDA CONFIRMED IT WILL CONTINUE TO FACILITATE IMPORTATION, OTHERS OF BUBS' INFANT FORMULA PRODUCTS IN US AFTER 31 DEC 2025</p></li></ul><p>Further company coverage: <span>BUB.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BUB.AU","symbol_name":"BUBS AUSTRALIA LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XX034:1","article_id":"2595277199","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595277199","pubTimestamp":1766970587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula SubmissionsDec 29 (Reuters) - Bubs Australia Ltd BUB.AX:FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONSCONFIRMS THAT IT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BUB.AU":"BUBS AUSTRALIA LTD","BK7509":"中概股","BK7141":"包装食品与肉类","BK7505":"食品股"},"translate_title":"BRIEF-Bubs Australia表示FDA继续审查Bubs提交的婴儿配方奶粉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUB.AU":0.9},"content_text":"BRIEF-Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula SubmissionsDec 29 (Reuters) - Bubs Australia Ltd BUB.AX:FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONSCONFIRMS THAT IT IS ON TRACK TO RECEIVE FDA APPROVALFDA CONFIRMED IT WILL CONTINUE TO FACILITATE IMPORTATION, OTHERS OF BUBS' INFANT FORMULA PRODUCTS IN US AFTER 31 DEC 2025Further company coverage: BUB.AX ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}